These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 35958548)
41. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk. Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769 [TBL] [Abstract][Full Text] [Related]
42. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains. Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537 [TBL] [Abstract][Full Text] [Related]
43. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. Calvaresi V; Wrobel AG; Toporowska J; Hammerschmid D; Doores KJ; Bradshaw RT; Parsons RB; Benton DJ; Roustan C; Reading E; Malim MH; Gamblin SJ; Politis A Nat Commun; 2023 Mar; 14(1):1421. PubMed ID: 36918534 [TBL] [Abstract][Full Text] [Related]
44. Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference. Durmaz V; Köchl K; Krassnigg A; Parigger L; Hetmann M; Singh A; Nutz D; Korsunsky A; Kahler U; König C; Chang L; Krebs M; Bassetto R; Pavkov-Keller T; Resch V; Gruber K; Steinkellner G; Gruber CC Sci Rep; 2022 Aug; 12(1):14534. PubMed ID: 36008461 [TBL] [Abstract][Full Text] [Related]
45. A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. Chang CW; Parsi KM; Somasundaran M; Vanderleeden E; Liu P; Cruz J; Cousineau A; Finberg RW; Kurt-Jones EA Viruses; 2022 Jun; 14(7):. PubMed ID: 35891350 [TBL] [Abstract][Full Text] [Related]
46. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Lupala CS; Ye Y; Chen H; Su XD; Liu H Biochem Biophys Res Commun; 2022 Jan; 590():34-41. PubMed ID: 34968782 [TBL] [Abstract][Full Text] [Related]
47. Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans. Xue X; Shi J; Xu H; Qin Y; Yang Z; Feng S; Liu D; Jian L; Hua L; Wang Y; Zhang Q; Huang X; Zhang X; Li X; Chen C; Guo J; Tang W; Liu J Sci Rep; 2021 Feb; 11(1):3187. PubMed ID: 33542420 [TBL] [Abstract][Full Text] [Related]
48. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. Fu L; Gilham D; Stotz SC; Sarsons CD; Rakai BD; Tsujikawa LM; Wasiak S; Johansson JO; Sweeney M; Wong NCW; Kulikowski E Int Immunopharmacol; 2023 Apr; 117():109929. PubMed ID: 36857935 [TBL] [Abstract][Full Text] [Related]
49. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. Niemeyer D; Stenzel S; Veith T; Schroeder S; Friedmann K; Weege F; Trimpert J; Heinze J; Richter A; Jansen J; Emanuel J; Kazmierski J; Pott F; Jeworowski LM; Olmer R; Jaboreck MC; Tenner B; Papies J; Walper F; Schmidt ML; Heinemann N; Möncke-Buchner E; Baumgardt M; Hoffmann K; Widera M; Thao TTN; Balázs A; Schulze J; Mache C; Jones TC; Morkel M; Ciesek S; Hanitsch LG; Mall MA; Hocke AC; Thiel V; Osterrieder K; Wolff T; Martin U; Corman VM; Müller MA; Goffinet C; Drosten C PLoS Biol; 2022 Nov; 20(11):e3001871. PubMed ID: 36383605 [TBL] [Abstract][Full Text] [Related]
50. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context. Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687 [TBL] [Abstract][Full Text] [Related]
51. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993 [TBL] [Abstract][Full Text] [Related]
52. Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2. Li Z; Zhang JZH Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454161 [TBL] [Abstract][Full Text] [Related]
53. Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern. Mandal N; Padhi AK; Rath SL J Mol Graph Model; 2022 Jul; 114():108194. PubMed ID: 35453047 [TBL] [Abstract][Full Text] [Related]
54. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443 [TBL] [Abstract][Full Text] [Related]
55. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733 [TBL] [Abstract][Full Text] [Related]